HLA-G expression in basal cell carcinomas of the skin recurring after radiotherapy
Détails
ID Serval
serval:BIB_FD4D860DC31F
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
HLA-G expression in basal cell carcinomas of the skin recurring after radiotherapy
Périodique
Clinical and Experimental Dermatology
ISSN
0307-6938 (Print)
Statut éditorial
Publié
Date de publication
07/2005
Volume
30
Numéro
4
Pages
422-5
Notes
Journal Article --- Old month value: Jul
Résumé
Basal cell carcinoma (BCC) of the skin represents the most common malignancy in the fair-skinned population worldwide. HLA-G is one of the molecules implicated in immunotolerance. To investigate the role of HLA-G in recurring BCCs, we constructed a tissue microarray containing 38 primary BCCs that underwent radiotherapy and 14 secondary BCCs recurring on the primary site after radiotherapy, and evaluated the HLA-G protein expression by immunohistochemistry. The HLA-G protein was most frequently expressed in aggressive sclerosing BCCs. Nodular BCC demonstrated the strongest HLA-G expression. Interestingly, tumor infiltrating mononuclear cells (TIMC) expressed the HLA-G molecule in BCCs that showed no recurrence. After comparing primary BCCs and BCCs relapsed after radiotherapy, we observed decreased HLA-G expression on tumor cells and the loss of HLA-G expression on TIMC in relapsed BCCs. After radiotherapy, immunobiology of BCC may change resulting in the down-regulation of HLA-G expression on tumor and on tumor-infiltrating cells.
Mots-clé
Carcinoma, Basal Cell/*immunology/radiotherapy
Follow-Up Studies
HLA Antigens/*metabolism
Histocompatibility Antigens Class I/*metabolism
Humans
Immune Tolerance
Immunoenzyme Techniques
Neoplasm Recurrence, Local/*immunology
Retrospective Studies
Skin Neoplasms/*immunology/radiotherapy
Pubmed
Web of science
Création de la notice
25/01/2008 17:55
Dernière modification de la notice
20/08/2019 17:28